Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lecigon in Parkinson's Disease
NCT07151378Phase 3Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Oct 2025
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of carbidopa/levodopa/entacapone in Parkinson's disease (PD), sponsored by University Hospital Tübingen. Started Oct 2025; status: recruiting.
02
Drugs
carbidopa/levodopa/entacapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07151378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07151378.